E. Karlafti, A. Hatzitolios, A. Karlaftis
Oct 1, 2013
Citations
0
Influential Citations
12
Citations
Journal
Journal of Pharmacy & Bioallied Sciences
Abstract
Moxonidine is the newest, second-generation, centrally acting antihypertensive agent. It has selective agonist activity at imidazoline I1 receptors and less adverse effects than the other centrally acting drugs. This fact authorizes the frequent use of moxonidine in clinical practice, as monotherapy or in combination with other antihypertensive agents. Also, moxonidine has beneficial effects in obese and metabolic syndrome and in target-organs, such as heart and kidneys.